The Medical Letter, Inc.

March 16, 2026

Description Two oral bacterial type II topoisomerase inhibitors. Indication Treatment of uncomplicated urogenital gonorrhea in patients ≥12 years old who weigh ≥45 kg (gepotidacin) or ≥35 kg (zoliflodacin); gepotidacin is only approved for use in patients with limited or no alternative treatment options. Efficacy In randomized trials in patients with uncomplicated urogenital gonorrhea, microbiological cure rates with 2 doses of gepotidacin or a single dose of zoliflodacin were noninferior to those with ceftriaxone plus azithromycin. Adverse Effects... Continue reading

View Complete Issue

More from Issue 1750

View Complete Issue

Previous Issue: 1749

March 2, 2026

View Complete Issue

Previous Issues

Coming Soon

Drugs for Cognitive Loss and Dementia

Aflibercept (Eylea HD) for Macular Edema following Retinal Vein Occlusion

Pivmecillinam (Pivya) for Uncomplicated UTI

Donate

Connect

FROM
ISSUE

1750

Depemokimab (Exdensur) for Severe Eosinophilic Asthma

The FDA has approved depemokimab (Exdensur – GSK), a long-acting interleukin-5 (IL-5) antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in patients ≥12 years old. Depemokimab is the fourth IL-5-directed treatment to be approved in the US for this indication; the IL-5 antagonists mepolizumab (Nucala) and reslizumab (Cinqair) and the IL-5 receptor alpha antagonist benralizumab (Fasenra) were approved earlier.1-3

MAINTENANCE TREATMENT — An inhaled corticosteroid (ICS) is the most effective maintenance treatment for asthma of any severity. Daily low-dose ICS treatment suppresses airway inflammation and reduces symptoms and exacerbations. Patients who remain symptomatic despite adherence to ICS monotherapy and good inhalation technique should receive maintenance treatment with a combination of an ICS … Continue reading